Lee Ainslie - Maverick Capital Ltd
Holding/activity history for Alnylam Pharmaceuticals (ALNY)
| Period | Shares | % of Portfolio | Activity | % Change to Portfolio | Reported Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2021 Q4 | 0 | 0.00 | Sell 100.00% | 0.01 | SEC | ||
| 2021 Q3 | 3,983 | 0.01 | Reduce 98.64% | 0.46 | $188.80 | $752,000 | SEC |
| 2021 Q2 | 292,683 | 0.47 | Reduce 63.24% | 0.65 | $169.52 | $49,616,000 | SEC |
| 2021 Q1 | 796,234 | 1.03 | Reduce 19.12% | 0.39 | $141.19 | $112,420,000 | SEC |
| 2020 Q4 | 984,502 | 2.05 | Add 1.76% | 0.04 | $129.97 | $127,956,000 | SEC |
| 2020 Q3 | 967,461 | 2.62 | Reduce 13.12% | 0.46 | $145.60 | $140,862,000 | SEC |
| 2020 Q2 | 1,113,608 | 3.47 | Reduce 16.88% | 0.52 | $148.11 | $164,936,000 | SEC |
| 2020 Q1 | 1,339,705 | 3.08 | Reduce 40.74% | 1.54 | $108.85 | $145,827,000 | SEC |
| 2019 Q4 | 2,260,897 | 3.79 | Reduce 29.85% | 1.14 | $115.17 | $260,388,000 | SEC |
| 2019 Q3 | 3,222,813 | 3.81 | Reduce 23.92% | 1.07 | $80.42 | $259,179,000 | SEC |
| 2019 Q2 | 4,236,016 | 4.46 | Add 31.95% | 1.08 | $72.56 | $307,365,000 | SEC |
| 2019 Q1 | 3,210,387 | 4.09 | Add 14.50% | 0.52 | $93.45 | $300,011,000 | SEC |
| 2018 Q4 | 2,803,951 | 3.07 | Add 85.44% | 1.41 | $72.91 | $204,436,000 | SEC |
| 2018 Q3 | 1,512,064 | 1.71 | Add 121.92% | 0.94 | $87.52 | $132,336,000 | SEC |
| 2018 Q2 | 681,354 | 0.81 | Buy | 0.81 | $98.49 | $67,107,000 | SEC |